Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer [Yahoo! Finance]
Ikena Oncology, Inc. (IKNA)
Company Research
Source: Yahoo! Finance
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases, today announced that Douglas Carlson has been appointed chief financial officer and chief business officer. Mr. Carlson brings over 20 years of biopharmaceutical experience with a multi-disciplinary background in corporate finance, venture capital, M&A, business development and commercial roles with both large and emerging growth companies. “We are excited to welcome Doug to Avalyn as we near our transition to a late-stage clinical company with the upcoming initiation of our Phase 2b study of AP01,” said Lyn Baranowski, CEO of Avalyn. “His proven track record in scaling organizations like ours, and leading and executing finance and capital strategies for privately held and publicly traded companies will be invaluable as we look to future opportunities and advance our pipeline of inhale
Show less
Read more
Impact Snapshot
Event Time:
IKNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKNA alerts
High impacting Ikena Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
IKNA
News
- Ikena Oncology, Inc. (NASDAQ: IKNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]Yahoo! Finance
- Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate UpdateGlobeNewswire
- Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum [Yahoo! Finance]Yahoo! Finance
- Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology ForumGlobeNewswire
IKNA
Earnings
- 3/12/24 - In-Line
IKNA
Sec Filings
- 5/13/24 - Form 10-Q
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- IKNA's page on the SEC website